Abstract
Background: Alzheimer’s disease is the most common form of dementia and mainly characterized by the accumulation the amyloid β (Aβ) peptide in the parenchyma and often around the blood vessels of the brain. The accumulation of Aβ in vessels walls is referred to as cerebral amyloid angiopathy (CAA). In a subset of AD cases CAA is observed in both capillaries and larger vessels which is designated as CAA type‐1. CAA type‐1 is associated with an increased neuroinflammatory response involving activated microglia and increased oxidative stress, which supposedly results in loss of blood‐brain barrier (BBB) integrity in CAA. Complement activation is an integral part of neuroinflammation associated with parenchymal Aβ deposits and CAA. However, a direct comparison of the complement activation in relation to plaque pathology and CAA type‐1 has not been made.Method: Using immunohistochemistry we performed a semi‐quantitative analysis on the expression and localization of complement factors C1q, C3, C4 and the membrane attack complex (MAC) in post mortem cortical brain tissue derived from AD cases with severe occurrence of CAA type‐1, AD cases without CAA and non‐demented control cases. In addition, label free quantitative mass spectrometry was applied to quantify complement components in whole cortical tissue lysates.Result: The complement factors C1q, C3 and C4 were found to be associated with CAA type‐1. No clear differences were observed in level of occurrence of C1q, C3 and C4 between AD cases with CAA type‐1, AD cases without CAA and non‐demented control cases. Interestingly, a subset of the AD cases with CAA type‐1 displayed MAC in affected vessels, whereas this was not observed in AD cases without CAA or control cases. Mass spectrometry analysis revealed an increase in C9, the primary component of MAC, in CAA type‐1 but not in AD without CAA.Conclusion: Early complement factors are present in all AD cases while the presence of MAC is restricted to a subset of CAA type‐1 cases, indicating full‐blown complement activation in CAA type‐1 but not in AD without CAA.